{
    "doi": "https://doi.org/10.1182/blood.V120.21.5172.5172",
    "article_title": "Chronic Iron Deficiency Anemia and Cancer Risk ",
    "article_date": "November 16, 2012",
    "session_type": "Regulation of Iron Metabolism",
    "abstract_text": "Abstract 5172 Background Iron deficiency anemia (IDA) is a common initial manifestation of gastrointestinal malignancies, but the relationship between chronic IDA and further cancer development is not established. Aims We would like to investigate the cancer risk of chronic IDA over a 10-year period in Taiwan. Methods We enrolled patients with iron deficiency anemia from a nationwide health registry in Taiwan during the period 2000\u20132009. All patients received at least 2 related examinations and were treated with iron supplement. Since IDA is an initial manifestation of many underlying malignancies, we excluded patients whose cancer developed within 1 year after IDA diagnosis. Standardized incidence ratios (SIRs) of cancers were calculated to compare the cancer incidence of chronic IDA patients to general population. The specific types of cancer were addressed. Results A total of 4, 373 patient with IDA were identified, and 132 (3. 02%) IDA patients developed cancer 1 year after enrollment (SIR 1. 52; 95% confidence interval [CI] 1. 27 \u2013 1. 80, p < 0. 001). The risks of kidney (SIR 5. 47, 95% CI 2. 73 \u2013 9. 78), bladder (SIR 3. 6, 95% CI 1. 64 \u2013 6. 83), liver (SIR 2. 80, 95% CI 1. 82 \u2013 4. 13), and colorectal malignancies (SIR 1. 93, 95% CI 1. 22 \u2013 2. 90) elevated. The risk of hematological malignancies were not increased in current study (SIR 1. 13, 95% CI 0. 31 \u2013 2. 89, p = 0. 758). Conclusions After exclusion of cancer development within the first year, IDA patients still had increased risk of cancer, especially kidney, bladder, liver, and colorectal malignancies. Table 1. Characteristics of patients with iron deficiency anemia  . Total . Male . Female . No. of patients 4373 746 3627 Person-years at risk 21856.6 3320.82 18535.8 Median follow-up, years (interquartile range) 4.87 (2.66 \u2013 7.18) 4.10 (2.27 \u2013 6.30) 5.06 (2.77 \u2013 7.31) Median age, years (interquartile range) 46.35 (38.37 \u2013 58.40) 65.95 (48.70 \u2013 76.83) 45.09 (37.23 \u2013 51.32) Age at diagnosis, years    0 \u2013 19 67 6 61 20 \u2013 39 1170 97 1073 40 \u2013 59 2090 206 1884 60 \u2013 79 774 316 458 \u2265 80 272 121 151 . Total . Male . Female . No. of patients 4373 746 3627 Person-years at risk 21856.6 3320.82 18535.8 Median follow-up, years (interquartile range) 4.87 (2.66 \u2013 7.18) 4.10 (2.27 \u2013 6.30) 5.06 (2.77 \u2013 7.31) Median age, years (interquartile range) 46.35 (38.37 \u2013 58.40) 65.95 (48.70 \u2013 76.83) 45.09 (37.23 \u2013 51.32) Age at diagnosis, years    0 \u2013 19 67 6 61 20 \u2013 39 1170 97 1073 40 \u2013 59 2090 206 1884 60 \u2013 79 774 316 458 \u2265 80 272 121 151 View Large Table 2. Standardized incidence ratios (SIRs) according to age at diagnosis, gender and duration of iron deficiency anemia  . Total . Male . Female . Characteristics . Observed . Expected . SIR (95% CI) . Observed . Expected . SIR (95% CI) . Observed . Expected . SIR (95% CI) . All cancers 132 86.75 1.52 (1.27 \u2013 1.80) 43 28.11 1.53 (1.11 \u2013 2.06) 89 58.64 1.52 (1.22 \u2013 1.87) Age at diagnosis, years          0 \u2013 19 0 0.00 0.00 (0.00 \u2013 900.53) 0 0.00 0.00 (0.00 \u2013 11307.26) 0 0.00 0.00 (0.00 \u2013 978.45) 20 \u2013 39 11 3.96 2.78 (1.39 \u2013 4.97) 0 0.23 0.00 (0.00 \u2013 16.27) 11 3.73 2.95 (1.47 \u2013 5.27) 40 \u2013 59 51 36.72 1.39 (1.03 \u2013 1.83) 8 3.46 2.31 (1.00 \u2013 4.56) 43 33.26 1.29 (0.94 \u2013 1.74) 60 \u2013 79 50 29.71 1.68 (1.25 \u2013 2.22) 25 14.99 1.67 (1.08 \u2013 2.46) 25 14.72 1.70 (1.10 \u2013 2.51) \u2265 80 20 16.35 1.22 (0.75 \u2013 1.89) 10 9.43 1.06 (0.51 \u2013 1.95) 10 6.91 1.45 (0.69 \u2013 2.66) Duration of iron deficiency anemia          \u2265 1 132 86.75 1.52 (1.27 \u2013 1.80) 43 28.11 1.53 (1.11 \u2013 2.06) 89 58.64 1.52 (1.22 \u2013 1.87) 1 \u2013 5 106 61.65 1.72 (1.41 \u2013 2.08) 38 21.20 1.79 (1.27 \u2013 2.46) 68 40.45 1.68 (1.31 \u2013 2.13) \u2265 5 26 25.10 1.04 (0.68 \u2013 1.52) 5 6.91 0.72 (0.23 \u2013 1.69) 21 18.18 1.15 (0.71 \u2013 1.77) . Total . Male . Female . Characteristics . Observed . Expected . SIR (95% CI) . Observed . Expected . SIR (95% CI) . Observed . Expected . SIR (95% CI) . All cancers 132 86.75 1.52 (1.27 \u2013 1.80) 43 28.11 1.53 (1.11 \u2013 2.06) 89 58.64 1.52 (1.22 \u2013 1.87) Age at diagnosis, years          0 \u2013 19 0 0.00 0.00 (0.00 \u2013 900.53) 0 0.00 0.00 (0.00 \u2013 11307.26) 0 0.00 0.00 (0.00 \u2013 978.45) 20 \u2013 39 11 3.96 2.78 (1.39 \u2013 4.97) 0 0.23 0.00 (0.00 \u2013 16.27) 11 3.73 2.95 (1.47 \u2013 5.27) 40 \u2013 59 51 36.72 1.39 (1.03 \u2013 1.83) 8 3.46 2.31 (1.00 \u2013 4.56) 43 33.26 1.29 (0.94 \u2013 1.74) 60 \u2013 79 50 29.71 1.68 (1.25 \u2013 2.22) 25 14.99 1.67 (1.08 \u2013 2.46) 25 14.72 1.70 (1.10 \u2013 2.51) \u2265 80 20 16.35 1.22 (0.75 \u2013 1.89) 10 9.43 1.06 (0.51 \u2013 1.95) 10 6.91 1.45 (0.69 \u2013 2.66) Duration of iron deficiency anemia          \u2265 1 132 86.75 1.52 (1.27 \u2013 1.80) 43 28.11 1.53 (1.11 \u2013 2.06) 89 58.64 1.52 (1.22 \u2013 1.87) 1 \u2013 5 106 61.65 1.72 (1.41 \u2013 2.08) 38 21.20 1.79 (1.27 \u2013 2.46) 68 40.45 1.68 (1.31 \u2013 2.13) \u2265 5 26 25.10 1.04 (0.68 \u2013 1.52) 5 6.91 0.72 (0.23 \u2013 1.69) 21 18.18 1.15 (0.71 \u2013 1.77) SIR Standardized incidence ratio; CI confidence interval View Large Table 3. Standardized incidence ratios (SIRs) for specific cancer types among patients with iron deficiency anemia  . Total . Site of cancers . Observed . Expected . SIR (95% CI) . All cancers 132 86.75 1.52 (1.27 \u2013 1.80) Head and neck 9 4.32 2.08 (0.95 \u2013 3.96) Digestive 57 27.93 2.04 (1.55 \u2013 2.64) Esophagus 2 0.98 2.05 (0.25 \u2013 7.41) Stomach 7 4.26 1.64 (0.66 \u2013 3.39) Colon and rectum 23 11.91 1.93 (1.22 \u2013 2.90) Anus 0 0.10 0.00 (0.00 \u2013 38.50) Liver and biliary tract 25 9.29 2.69 (1.74 \u2013 3.97) Pancreas 0 1.40 0.00 (0.00 \u2013 2.63) Lung and mediastinum 5 9.90 0.50 (0.16 \u2013 1.18) Bone and Soft tissue 0 0.66 0.00 (0.00 \u2013 5.58) Skin 1 1.72 0.58 (0.01 \u2013 3.24) Breast 13 16.44 0.79 (0.42 \u2013 1.35) Genitourinary 37 16.39 2.26 (1.59 \u2013 3.11) Cervix 3 4.05 0.74 (0.15 \u2013 2.16) Uterus 6 2.35 2.55 (0.94 \u2013 5.56) Ovary 5 2.04 2.45 (0.80 \u2013 5.73) Prostate 3 3.44 0.87 (0.18 \u2013 2.55) Bladder 9 2.50 3.60 (1.64 \u2013 6.83) Kidney 11 2.01 5.47 (2.73 \u2013 9.78) Thyroid 3 2.74 1.09 (0.23 \u2013 3.20) Hematologic malignancies 4 3.55 1.13 (0.31 \u2013 2.89) All Others 3 3.09 0.97 (0.20 \u2013 2.84) . Total . Site of cancers . Observed . Expected . SIR (95% CI) . All cancers 132 86.75 1.52 (1.27 \u2013 1.80) Head and neck 9 4.32 2.08 (0.95 \u2013 3.96) Digestive 57 27.93 2.04 (1.55 \u2013 2.64) Esophagus 2 0.98 2.05 (0.25 \u2013 7.41) Stomach 7 4.26 1.64 (0.66 \u2013 3.39) Colon and rectum 23 11.91 1.93 (1.22 \u2013 2.90) Anus 0 0.10 0.00 (0.00 \u2013 38.50) Liver and biliary tract 25 9.29 2.69 (1.74 \u2013 3.97) Pancreas 0 1.40 0.00 (0.00 \u2013 2.63) Lung and mediastinum 5 9.90 0.50 (0.16 \u2013 1.18) Bone and Soft tissue 0 0.66 0.00 (0.00 \u2013 5.58) Skin 1 1.72 0.58 (0.01 \u2013 3.24) Breast 13 16.44 0.79 (0.42 \u2013 1.35) Genitourinary 37 16.39 2.26 (1.59 \u2013 3.11) Cervix 3 4.05 0.74 (0.15 \u2013 2.16) Uterus 6 2.35 2.55 (0.94 \u2013 5.56) Ovary 5 2.04 2.45 (0.80 \u2013 5.73) Prostate 3 3.44 0.87 (0.18 \u2013 2.55) Bladder 9 2.50 3.60 (1.64 \u2013 6.83) Kidney 11 2.01 5.47 (2.73 \u2013 9.78) Thyroid 3 2.74 1.09 (0.23 \u2013 3.20) Hematologic malignancies 4 3.55 1.13 (0.31 \u2013 2.89) All Others 3 3.09 0.97 (0.20 \u2013 2.84) SIR Standardized incidence ratio; CI confidence interval View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "cancer risk",
        "iron deficiency anemia",
        "cancer",
        "systemic inflammatory response syndrome",
        "hematologic neoplasms",
        "follow-up",
        "gastrointestinal cancer",
        "iron supplement",
        "kidney",
        "liver"
    ],
    "author_names": [
        "Chia-Jen Liu, MD",
        "Kuo-Wei Chen, MD",
        "Yu-Wen Hu, MD",
        "Ying-Chung Hong, MD",
        "Yu-Chung Huang, MD",
        "Tzeon-Jye Chiou, MD",
        "Cheng-Hwai Tzeng, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Chia-Jen Liu, MD",
            "author_affiliations": [
                "Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Kuo-Wei Chen, MD",
            "author_affiliations": [
                "Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yu-Wen Hu, MD",
            "author_affiliations": [
                "Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ying-Chung Hong, MD",
            "author_affiliations": [
                "Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yu-Chung Huang, MD",
            "author_affiliations": [
                "Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tzeon-Jye Chiou, MD",
            "author_affiliations": [
                "Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cheng-Hwai Tzeng, MD",
            "author_affiliations": [
                "Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-23T04:12:50",
    "is_scraped": "1"
}